Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by pcoopman
Last modified by standudu
Group name EquipePC
Item Type Journal Article
Title Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management
Creator Vendrell et al.
Author Julie A. Vendrell
Author Frédéric Tran Mau-Them
Author Benoît Béganton
Author Sylvain Godreuil
Author Peter Coopman
Author Jérôme Solassol
Abstract Circulating tumoral DNA (ctDNA), commonly named "liquid biopsy", has emerged as a new promising noninvasive tool to detect biomarker in several cancers including lung cancer. Applications involving molecular analysis of ctDNA in lung cancer have increased and encompass diagnosis, response to treatment, acquired resistance and prognosis prediction, while bypassing the problem of tumor heterogeneity. ctDNA may then help perform dynamic genetic surveillance in the era of precision medicine through indirect tumoral genomic information determination. The aims of this review were to examine the recent technical developments that allowed the detection of genetic alterations of ctDNA in lung cancer. Furthermore, we explored clinical applications in patients with lung cancer including treatment efficiency monitoring, acquired therapy resistance mechanisms and prognosis value.
Publication International Journal of Molecular Sciences
Volume 18
Issue 2
Date Jan 29, 2017
Journal Abbr Int J Mol Sci
Language eng
DOI 10.3390/ijms18020264
ISSN 1422-0067
Library Catalog PubMed
Extra 00000 PMID: 28146051 PMCID: PMC5343800
Tags Biomarkers, Tumor, Biopsy, Diagnostic Tests, Routine, Disease Management, DNA, Neoplasm, first-last-corresponding, Genomics, High-Throughput Nucleotide Sequencing, Humans, lung cancer, Lung Neoplasms, molecular diagnosis, Neoplastic Cells, Circulating, Polymerase Chain Reaction, Precision Medicine, Prognosis, review, routine practice, targeted therapies, Tumor Burden
Date Added 2019/09/13 - 11:56:02
Date Modified 2020/10/04 - 14:02:01
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés